JAMA Clinical Reviews
Amyotrophic lateral sclerosis (ALS), which affects about 25 000 individuals in the US, causes progressive weakness but has varied presentations. Several FDA-approved medications are now available for ALS. Author John Ravits, MD, of UC San Diego School of Medicine joins JAMA Deputy Editor Mary M. McDermott, MD, to discuss current evidence regarding diagnosis and treatment of ALS. Related Content: * Amyotrophic Lateral Sclerosis [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.6385?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links] * Pridopidine in Amyotrophic Lateral Sclerosis [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.26429?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links] * What Is Amyotrophic Lateral Sclerosis? [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2022.19305?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links] * CNM-Au8 in Amyotrophic Lateral Sclerosis [https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.27643?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links] * Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis [https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2026.0230?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links] * Traumatic Brain Injury and Risk of Amyotrophic Lateral Sclerosis [https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.35119?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links]
489 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de JAMA Clinical Reviews!